This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
Expenditure on reimbursed health products continues to rise in France, with total spending on reimbursed medicines reaching €37.2 billion in 2024, representing...
Reference country selection The model provided guidance on reference countries, defined by the G7 countries plus Denmark and Switzerland. Reference...
